Evidence map›Paper›PMID 35211122›Full record

SynthesisFrontiers in immunology2022

The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.

Cheng-Long Han, Guang-Xiao Meng, Zi-Niu Ding, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Lun-Jie Yan, Hui Liu, Bao-Wen Tian, Long-Shan Yang and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 8 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 8 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Cheng-Long HanDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Guang-Xiao MengDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Zi-Niu DingDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Zhao-Ru DongDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Zhi-Qiang ChenDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Jian-Guo HongDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Lun-Jie YanDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Hui LiuDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Bao-Wen TianDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Long-Shan YangDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Jun-Shuai XueDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Tao LiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The relationship between baseline C-reactive protein (CRP) level and the prognosis of cancer patients receiving immune checkpoint inhibitor (ICI) treatment remains controversial. The aim of this meta-analysis was to clarify whether baseline CRP level can serve as a biomarker to predict the efficiency of ICI therapy. Methods: All associated articles published in the Cochrane Library, EMBASE, and PubMed databases from the inception of the database to December 30, 2021, were retrieved. Progression-free survival (PFS) and overall survival (OS) outcomes were meta-analyzed using the random-effects model and adjusted using the trim-and-fill method because of publication bias. Results: Thirty-three studies (6,124 patients) conducted between 2013 and 2021 were identified. The pooled outcomes implied that high baseline CRP level patients had significantly worse OS (adjusted pooled value for univariate and multivariate analysis outcomes: HR = 1.48, 95% CI = 1.41-1.56; HR = 1.46, 95% CI = 1.34-1.59) and PFS (adjusted pooled value for univariate and multivariate analysis outcomes: HR = 1.29, 95% CI = 1.15-1.45; HR = 1.20, 95% CI = 1.02-1.40) than low baseline CRP level patients, irrespective of cancer or ICI type. Further analysis indicated that 1 mg/dl was appropriate as a cutoff value for determining the low or high level of baseline CRP to predict the OS or PFS of cancer patients receiving ICI treatment (univariate analysis: HR = 1.56, 95% CI = 1.24-1.97, Conclusions: High baseline CRP level (>1 mg/dl) may be an indicator for worse OS and PFS of cancer patients treated with ICIs. More high-quality prospective studies are warranted to assess the predictive value of CRP for ICI treatment.

Indexed as

Biomarkers, TumorC-Reactive ProteinHumansImmune Checkpoint InhibitorsNeoplasmsPredictive Value of TestsSurvival AnalysisBiomarkers, TumorC-Reactive ProteinImmune Checkpoint InhibitorscancerC-reactive proteinimmune checkpoint inhibitorsmeta-analysispredictive potentialprognosis

Identifiers

PMID35211122
PMCPMC8861087
OpenAlexW4210897626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.